Suvorexant: a promising, novel treatment for insomnia.

Article Details

Citation

Copy to clipboard

Lee-Iannotti JK, Parish JM

Suvorexant: a promising, novel treatment for insomnia.

Neuropsychiatr Dis Treat. 2016 Feb 25;12:491-5. doi: 10.2147/NDT.S31495. eCollection 2016.

PubMed ID

26955275 [ View in PubMed

]

Abstract

Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Suvorexant	Cytochrome P450 3A4	Protein	Humans	No	Substrate	Details